Introduction: Asthma is one of the most common chronic diseases and affects around 334 million people worldwide. The estimated prevalence of severe asthma is 3–10% of the asthmatic population. Mepolizumab has demonstrated efficacy in reducing exacerbations, oral corticosteroid use, and improving quality of life, asthma control, and lung function in patients with severe eosinophilic asthma (SEA). Our study aimed to check the response to mepolizumab in a series of severe asthma patients regarding exacerbations, oral corticosteroid use, asthma control, quality of life, and lung function and to compare the response between patients with and without nasal polyps. Method: This is a retrospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) performed in eight hospitals of the Region of Murcia (Spain) under routine clinical practice conditions. We included patients diagnosed with SEA who completed at least 1 year of treatment with mepolizumab. We analyzed clinical characteristics, drug tolerance, and effectiveness: exacerbations, ACT, miniAQLQ, forced expiratory volume in 1 s (FEV1), and use of oral corticosteroids. We also compared the results between patients with and without nasal polyps. Results: The median of exacerbations before treatment was 3 and decreased to 0 after treatment (mean decrease of 77.4%). The median diary oral prednisone intake was 15 mg before treatment and 5 mg after treatment (mean 56% reduction). We have obtained a significant improvement in other variables: ED visits and hospitalizations, asthma control (ACT), quality of life (miniAQLQ), and lung function (FEV1). Thirty-four out of 70 patients (48.57%) fulfilled the criteria of super-responder, and 17 out of 70 (24.29%) had a complete response. More patients in the group with nasal polyps fulfilled the criteria of super-responder and complete response to mepolizumab. Conclusions: Mepolizumab is a safe and effective treatment for SEA patients, improving exacerbations, oral corticosteroid intake, asthma control, quality of life, and lung function. In patients with associated nasal polyposis, there is a statistically significant higher proportion of super-responders and complete responders.

1.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators; Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.
2.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.
3.
Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
4.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.
5.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.
6.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97.
7.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
8.
Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, Martínez Moragón E, Banas Conejero D, Sánchez Herrero MG, et al. REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES Study. Drugs. 2021;81(15):1763–74.
9.
Miralles-López JC, Andújar-Espinosa R, Bravo-Gutiérrez FJ, Castilla-Martínez M, Flores-Martín I, Alemany-Francés ML, et al. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol Immunopathol. 2022;50(6):163–8.
10.
Alvarez-Gutierrez FJ, Blanco-Aparicio M, Plaza V, Cisneros C, Garcia-Rivero JL, Padilla A, et al. Documento de consenso de asma grave en adultos. Actualizacion 2020. Open Respir Arch. 2020;2(3):158–74.
11.
Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a delphi consensus. J Allergy Clin Immunol Pract. 2023:S2213-2198(23)00816-4. Ahead of print.
12.
Loli-Ausejo D, Perdomo G, Mascaró B, Martínez-Olondris P, Sánchez-Fernández MC, Mullol J, et al. Mepolizumab for treatment of severe eosinophilic asthma: a 5-year real-world experience. J Investig Allergol Clin Immunol. 2023;33(3):209–10.
13.
Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, et al. Real-world effectiveness and the characteristics of a “Super-Responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500.
14.
Rodríguez-García C, Blanco-Aparicio M, Nieto-Fontarigo JJ, Blanco-Cid N, Gonzalez-Fernandez C, Mosteiro-Añon M, et al. Efficacy of mepolizumab in usual clinical practice and characteristics of responders. Respir Med. 2021;187:106595.
15.
Cakmak ME, Öztop N, Yeğit OO, Özdedeoğlu Ö. Evaluation of the clinical features and laboratory data of patients with severe eosinophilic asthma classified as super-responders, partial responders, or nonresponders to mepolizumab treatment: a real-life study. Int Arch Allergy Immunol. 2023;184:736–43.
16.
Arismendi E, Cisneros C, Blanco-Aparicio M, Martínez-Moragón E, Quirce S, Bañas Conejero D, et al. REDES Study: mepolizumab is effective in patients with severe asthma and comorbid nasal polyps. J Investig Allergol Clin Immunol. 2023;33(6):0.
17.
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, et al. Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2023;11(3):885–95.e13.
18.
Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FE, Lee JK, et al. REALITI-A Study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10:2646–56.
You do not currently have access to this content.